Genomics in personalized cancer medicine and its impact on early drug development in China: report from the 6th Annual Meeting of the US Chinese Anti-Cancer Association (USCACA) at the 50th ASCO Annual Meeting.
- Author:
Wei ZHANG
1
;
Shi-Yuan CHENG
;
Li-Fang HOU
;
Li YAN
;
Yun-Guang TONG
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Agents; Awards and Prizes; Chicago; China; Drug Discovery; Genomics; Humans; Medical Oncology; Neoplasms; Precision Medicine; Societies, Medical; United States
- From:Chinese Journal of Cancer 2014;33(8):371-375
- CountryChina
- Language:English
- Abstract: The 6th Annual Meeting of the United States Chinese Anti-Cancer Association (USCACA) was held in conjunction with the 50th Annual Meeting of American Society of Clinical Oncology (ASCO) on May 30, 2014 in Chicago, Illinois, the United States of America. With a focus on personalized medicine, the conference featured novel approaches to investigate genomic aberrations in cancer cells and innovative clinical trial designs to expedite cancer drug development in biomarker-defined patient populations. A panel discussion further provided in-depth advice on advancing development of personalized cancer medicines in China. The conference also summarized USCACA key initiatives and accomplishments, including two awards designated to recognize young investigators from China for their achievements and to support their training in the United States. As an effort to promote international collaboration, USCACA will team up with Chinese Society of Clinical Oncology (CSCO) to host a joint session on "Breakthrough Cancer Medicines" at the upcoming CSCO Annual Meeting on September 20th, 2014 in Xiamen, China.
